Header

UZH-Logo

Maintenance Infos

Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months


Edwards, P; Arango, M; Balica, L; Cottingham, R; El-Sayed, H; Farrell, B; Fernandes, J; Gogichaisvili, T; Golden, N; Hartzenberg, B; Husain, M; Ulloa, M I; Jerbi, Z; Khamis, H; Komolafe, E; Laloë, V; Lomas, G; Ludwig, S; Mazairac, G; Muñoz Sanchéz, M; Nasi, L; Olldashi, F; Plunkett, P; Roberts, I; Sandercock, P; Shakur, H; Soler, C; Stocker, R; Svoboda, P; Trenkler, S; Venkataramana, N K; Wasserberg, J; Yates, D; Yutthakasemsunt, S (2005). Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet, 365(9475):1957-1959.

Abstract

MRC CRASH is a randomised controlled trial (ISRCTN74459797) of the effect of corticosteroids on death and disability after head injury. We randomly allocated 10,008 adults with head injury and a Glasgow Coma Scale score of 14 or less, within 8 h of injury, to a 48-h infusion of corticosteroid (methylprednisolone) or placebo. Data at 6 months were obtained for 9673 (96.7%) patients. The risk of death was higher in the corticosteroid group than in the placebo group (1248 [25.7%] vs 1075 [22.3%] deaths; relative risk 1.15, 95% CI 1.07-1.24; p=0.0001), as was the risk of death or severe disability (1828 [38.1%] vs 1728 [36.3%] dead or severely disabled; 1.05, 0.99-1.10; p=0.079). There was no evidence that the effect of corticosteroids differed by injury severity or time since injury. These results lend support to our earlier conclusion that corticosteroids should not be used routinely in the treatment of head injury.

Abstract

MRC CRASH is a randomised controlled trial (ISRCTN74459797) of the effect of corticosteroids on death and disability after head injury. We randomly allocated 10,008 adults with head injury and a Glasgow Coma Scale score of 14 or less, within 8 h of injury, to a 48-h infusion of corticosteroid (methylprednisolone) or placebo. Data at 6 months were obtained for 9673 (96.7%) patients. The risk of death was higher in the corticosteroid group than in the placebo group (1248 [25.7%] vs 1075 [22.3%] deaths; relative risk 1.15, 95% CI 1.07-1.24; p=0.0001), as was the risk of death or severe disability (1828 [38.1%] vs 1728 [36.3%] dead or severely disabled; 1.05, 0.99-1.10; p=0.079). There was no evidence that the effect of corticosteroids differed by injury severity or time since injury. These results lend support to our earlier conclusion that corticosteroids should not be used routinely in the treatment of head injury.

Statistics

Citations

Dimensions.ai Metrics
385 citations in Web of Science®
455 citations in Scopus®
617 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

1 download since deposited on 16 Sep 2009
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Intensive Care Medicine
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2005
Deposited On:16 Sep 2009 11:35
Last Modified:01 Oct 2019 11:27
Publisher:Elsevier
ISSN:0140-6736
OA Status:Closed
Publisher DOI:https://doi.org/10.1016/S0140-6736(05)66552-X
PubMed ID:15936423

Download

Closed Access: Download allowed only for UZH members